Nephro Care India Limited Stock Price Today (NSE: NEPHROCARE)
Fundamental Score
Nephro Care India Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Nephro Care India Limited share price today is ₹65.95, down 2.37% on NSE/BSE as of 17 July 2026. Nephro Care India Limited (NEPHROCARE) is a Small-cap company in the Hospital sector with a market capitalisation of ₹108.73 (Cr). The 52-week high for NEPHROCARE share price is ₹183.00 and the 52-week low is ₹51.65. At a P/E ratio of 32.26x, NEPHROCARE is currently trading below its industry average P/E of 48.79x. The company has a Return on Equity (ROE) of 6.11% and a debt-to-equity ratio of 0.00.
Nephro Care India Limited Share Price Chart — NSE/BSE Historical Performance
Nephro Care India Limited share price chart: -3.86% return over the past month. 52-week high ₹183.00, 52-week low ₹51.65.
Nephro Care India Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹63.40 | ₹67.40 | ₹62.75 | ₹65.95 | 26.80K (Cr) | |
| ₹69.00 | ₹70.60 | ₹67.55 | ₹67.55 | 8.00K (Cr) | |
| ₹70.60 | ₹70.60 | ₹68.00 | ₹68.60 | 8.00K (Cr) | |
| ₹68.85 | ₹71.00 | ₹68.85 | ₹68.85 | 24.00K (Cr) | |
| ₹80.00 | ₹83.10 | ₹79.00 | ₹80.25 | 16.00K (Cr) | |
| ₹80.00 | ₹83.80 | ₹78.00 | ₹78.40 | 30.00K (Cr) | |
| ₹85.00 | ₹85.00 | ₹78.35 | ₹79.55 | 22.00K (Cr) | |
| ₹88.00 | ₹88.00 | ₹85.35 | ₹87.00 | 8.80K (Cr) | |
| ₹80.80 | ₹83.40 | ₹80.55 | ₹82.85 | 13.20K (Cr) | |
| ₹80.50 | ₹81.95 | ₹80.00 | ₹80.55 | 3.20K (Cr) |
Nephro Care India Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹70.60 | ₹70.60 | ₹62.75 | ₹65.95 | -6.59% | |
| ₹68.85 | ₹71.00 | ₹68.85 | ₹68.85 | +0.00% | |
| ₹80.50 | ₹88.00 | ₹78.00 | ₹80.25 | -0.31% | |
| ₹55.90 | ₹88.90 | ₹53.00 | ₹88.60 | +58.50% | |
| ₹63.50 | ₹63.50 | ₹51.65 | ₹52.30 | -17.64% | |
| ₹101.20 | ₹116.05 | ₹70.00 | ₹82.45 | -18.53% | |
| ₹112.25 | ₹123.00 | ₹95.00 | ₹100.20 | -10.73% | |
| ₹131.20 | ₹131.40 | ₹107.50 | ₹110.50 | -15.78% | |
| ₹131.95 | ₹156.35 | ₹131.95 | ₹148.00 | +12.16% | |
| ₹140.10 | ₹145.00 | ₹131.35 | ₹139.00 | -0.79% | |
| ₹154.00 | ₹173.95 | ₹133.55 | ₹142.85 | -7.24% | |
| ₹146.90 | ₹183.00 | ₹133.05 | ₹155.05 | +5.55% |
AI Research Briefing
Powered by Gemini · 2026-04-13
Expensive micro-cap dialysis play with GST risk; avoid until valuation becomes rational.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Nephro Care is fighting a Cr GST bill in High Court after an appeal was blocked. A significant price movement was observed on April 9, 2026.
CORE STORY (THE REAL GAME)
- Sales CAGR 5Y of 143.29%
- InCred Securities initiated coverage with an 'ADD' rating and a target price of ₹613
- Asset-light model with 52% of clinics operating within partner hospitals and PPP clinics
- Significant order wins
- Successful resolution of GST issue
- Faster-than-expected expansion of dialysis centers
- Micro/SME cap - liquidity risk
- High P/E of 65.09x vs industry P/E of 52.84x [cite: brief]
- GST bill of ₹2.51 Cr
FII decreased holdings by 0.03%, DII decreased holdings by 1.2% [cite: brief].
Growing demand for healthcare services in India provides a tailwind.
No - Free Cash Flow 5Y: ₹-22.86 Cr [cite: brief]
3-6 month thesis: Expect a correction as valuation normalizes. Monitor for successful resolution of GST issue and execution of expansion plans.
Primary Thesis Risk
Overvaluation and reliance on government contracts create significant downside risk.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Nephro Care India Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Nephro Care India Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of NEPHROCARE across key market metrics for learning purposes.
Positive Indicators
7 factors identified
Attractive Valuation (P/E: 32.26 vs Industry: 48.79)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Consistent Growth Track Record (117.57% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Strong Profit Growth Track Record (106.38% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (30.00x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (61.71%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
6 factors identified
Below-Average Return on Equity (6.11%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (8.70%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Weak Earnings Growth (-53.09% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Negative Free Cash Flow (₹-28.61 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Limited Institutional Interest (FII+DII: 2.03%)
Observation: Low institutional participation may affect liquidity.
Analysis: Limited institutional interest may indicate size constraints or visibility issues.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Nephro Care India Limited vs Hospital Peers
Peer Comparison - Hospital
Compare Nephro Care India Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
45.4/100 | ₹65.95₹66 | ₹108.73₹108.73 | 32.26Average 32.3 Average | 6.11%Poor 6.11% Poor | 8.70%Poor 8.70% Poor | 0.00Excellent 0.0 Excellent | 106.38%Excellent 106.38% Excellent | 117.57%Excellent 117.57% Excellent | 0.00% | |
Apollo Hospitals Enterprise LtdApollo Hospital... APOLLOHOSP • 508869 | 62.1/100 | ₹8934.00₹8934 | ₹128448.55₹128448.55 | 65.68Average 65.7 Average | 22.11%Excellent 22.11% Excellent | 17.89%Good 17.89% Good | 0.90Good 0.9 Good | 77.79%Excellent 77.79% Excellent | 19.03%Excellent 19.03% Excellent | 0.22% |
Max Healthcare Institute LtdMax Healthcare ... MAXHEALTH • 543220 | 56.9/100 | ₹1102.70₹1103 | ₹107422.79₹107422.79 | 72.42Average 72.4 Average | 14.74%Average 14.74% Average | 14.71%Average 14.71% Average | 0.32Excellent 0.3 Excellent | 60.01%Excellent 60.01% Excellent | 27.27%Excellent 27.27% Excellent | 0.18% |
Fortis Healthcare LtdFortis Healthca... FORTIS • 532843 | 56.8/100 | ₹976.15₹976 | ₹73687.64₹73687.64 | 69.60Average 69.6 Average | 11.26%Average 11.26% Average | 13.47%Average 13.47% Average | 0.35Excellent 0.3 Excellent | 64.38%Excellent 64.38% Excellent | 17.76%Excellent 17.76% Excellent | 0.10% |
Aster DM Healthcare LtdAster DM Health... ASTERDM • 540975 | 37.2/100 | ₹824.60₹825 | ₹71917.90₹71917.90 | 176.20Average 176.2 Average | 10.70%Average 10.70% Average | 11.40%Average 11.40% Average | 0.49Excellent 0.5 Excellent | 22.57%Excellent 22.57% Excellent | -11.61%Poor -11.61% Poor | 0.61% |
Narayana Hrudayalaya LtdNarayana Hruday... NH • 539551 | 68.3/100 | ₹2037.40₹2037 | ₹41592.95₹41592.95 | 48.83Average 48.8 Average | 20.87%Excellent 20.87% Excellent | 15.36%Good 15.36% Good | 1.29Average 1.3 Average | 155.30%Excellent 155.30% Excellent | 25.04%Excellent 25.04% Excellent | 0.22% |
Global Health LtdGlobal Health L... MEDANTA • 543654 | 59.9/100 | ₹1338.50₹1339 | ₹35993.93₹35993.93 | 64.59Average 64.6 Average | 15.17%Good 15.17% Good | 17.14%Good 17.14% Good | 0.30Excellent 0.3 Excellent | 80.71%Excellent 80.71% Excellent | 24.97%Excellent 24.97% Excellent | 0.04% |
13.9/100 | ₹807.95₹808 | ₹33947.05₹33947.05 | 136.88Average 136.9 Average | 11.31%Average 11.31% Average | 9.29%Poor 9.29% Poor | 1.89Average 1.9 Average | 4.19%Average 4.19% Average | 24.04%Excellent 24.04% Excellent | 0.00% | |
Dr Agarwals Health Care LtdDr Agarwals Hea... AGARWALEYE • 544350 | 48.5/100 | ₹493.75₹494 | ₹15618.15₹15618.15 | 117.89Average 117.9 Average | 6.81%Poor 6.81% Poor | 11.12%Average 11.12% Average | 0.53Good 0.5 Good | 34.42%Excellent 34.42% Excellent | 34.58%Excellent 34.58% Excellent | 0.00% |
60/100 | ₹1499.80₹1500 | ₹9829.95₹9829.95 | 51.90Average 51.9 Average | 13.06%Average 13.06% Average | 14.80%Average 14.80% Average | 0.38Excellent 0.4 Excellent | 142.78%Excellent 142.78% Excellent | 25.27%Excellent 25.27% Excellent | 0.07% | |
42.7/100 | ₹646.85₹647 | ₹9663.25₹9663.25 | 336.09Average 336.1 Average | 2.55%Poor 2.55% Poor | 8.31%Poor 8.31% Poor | 1.30Average 1.3 Average | 17.65%Excellent 17.65% Excellent | 20.33%Excellent 20.33% Excellent | 0.00% | |
Top Hospital Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Apollo Hospitals Enterprise Ltd share price128448.55 Cr
- Max Healthcare Institute Ltd share price107422.79 Cr
- Fortis Healthcare Ltd share price73687.64 Cr
- Aster DM Healthcare Ltd share price71917.90 Cr
- Narayana Hrudayalaya Ltd share price41592.95 Cr
Nephro Care India Limited PE Ratio History
Historical price-to-earnings ratio for NEPHROCARE — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2024 | ₹2.73 | ₹184.00 | 67.4x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Nephro Care India Limited Quarterly Performance
Latest quarterly metrics for NEPHROCARE — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
N/A
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
N/A
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
117.57%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
106.38%
Compounded annual net profit growth over 5 years
Nephro Care India Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for NEPHROCARE — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Nephro Care India Limited Financial Statements
Annual income statement, balance sheet and cash flow for Nephro Care India Limited (NEPHROCARE) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Nephro Care India Limited
About NEPHROCARE (Nephro Care India Limited)
Nephro Care India Limited (NEPHROCARE) is listed on the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE) of India. The company operates in the Hospital sector with a c...urrent market capitalisation of ₹108.73 (Cr). Nephro Care India Limited has delivered a Return on Equity (ROE) of 6.11% and a ROCE of 8.70%. The debt-to-equity ratio stands at 0.00, reflecting the company's capital structure. Investors tracking NEPHROCARE share price can monitor key metrics including P/E ratio, promoter holding of 61.71%, and quarterly earnings growth.
Company Details
NEPHROCARE Share Price: Frequently Asked Questions
What is the current share price of Nephro Care India Limited?
Nephro Care India Limited (NEPHROCARE) trades at ₹65.95 on NSE. Market cap ₹108.73 (Cr). Educational data only.
What is the P/E ratio of Nephro Care India Limited?
Nephro Care India Limited has a P/E of 32.26x vs industry average 48.79x.
What is the Bull Run score for Nephro Care India Limited?
Nephro Care India Limited has a Bull Run score of 45.4/100 based on 25+ financial parameters.
Does Nephro Care India Limited pay dividends?
Nephro Care India Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Nephro Care India Limited?
Nephro Care India Limited has ROE of 6.11%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Nephro Care India Limited?
Nephro Care India Limited has debt-to-equity of 0.00.
Is Nephro Care India Limited a good investment?
Bull Run gives Nephro Care India Limited a score of 45.4/100. This is not investment advice — consult a SEBI-registered advisor.